Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry

2009/11/01 by Stephen Waldek, Manesh R. Patel, Maryam Banikazemi +2 · 277 citations
Medicine · #Biomedical Research and Pathophysiology #Cause of death #Disease #Disease registry #Fabry disease #Glycogen Storage Diseases and Myoclonus #Internal medicine #Life expectancy #Lysosomal Storage Disorders Research #Medicine #Pediatrics #Population

paper · pdf · doi:10.1097/gim.0b013e3181bb05bb

published in Genetics in Medicine 11(11), 790-796 (Elsevier BV)

crossref issued 2009/11/01 · crossref published 2009/11/01 · crossref published-print 2009/11/01 · openalex publication_date 2009/11/01 · crossref created 2009/11/10 · openalex created_date 2025/10/10 · crossref deposited 2025/10/22 · crossref indexed 2026/06/17 · openalex updated_date 2026/07/28

Citations

• Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease

Cited by

• Fabry disease in cardiology practice: Literature review and expert point of view
• Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
• European expert consensus statement on therapeutic goals in Fabry disease
• Fabry disease [wikipedia]